Cyclophosphamide induces differentiation of Th17 cells in cancer patients.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 21148486.
- Also identified by DOI 10.1158/0008-5472.CAN-10-1259.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4(+) T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact on the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients.
Medical subject headings
- Antineoplastic Agents, Alkylating
- Cell Differentiation
- Cyclophosphamide
- Neoplasms
- Th17 Cells